T. Wilson

发表

EFFECTIVE SUPPRESSION OF DIHYDROTESTOSTERONE (DHT) BY GI198745, A NOVEL, DUAL 5 ALPHA REDUCTASE INHIBITOR

D. Hermann, R. V. Clark, Hoda Gabriel, 1999 .

RELATIONSHIP BETWEEN SERUM PSA AND TOTAL PROSTATE AND TRANSITION ZONE VOLUME IN MEN WITH CLINICAL BPH

P. Boyle, C. Roehrborn, R. V. Clark, 1999 .

Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program

J. Davidson, R. Reinhardt, A. Nino, 2017, Postgraduate medicine.

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study

C. Roehrborn, F. Montorsi, P. Siami, 2009, Prostate Cancer and Prostatic Diseases.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

D. Tindall, D. Bostwick, T. Tammela, 2014, Urology.

The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

N. Monga, Daniel A. Rubinger, Z. Su, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

C. Roehrborn, G. Andriole, R. Rittmaster, 2011, European urology.

Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

C. Roehrborn, F. Montorsi, J. Nickel, 2011, The Journal of urology.

The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.

C. Roehrborn, L. Marks, T. Wilson, 2007, The Journal of urology.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

D. Tindall, D. Bostwick, T. Tammela, 2011, The Journal of urology.

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

C. Roehrborn, F. Montorsi, B. Chung, 2009, Prostate Cancer and Prostatic Diseases.

Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs

Y. Seino, H. Nakajima, M. C. Carr, 2017, Current medical research and opinion.

Weekly glucagon‐like peptide‐1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled study

Y. Seino, H. Nakajima, M. C. Carr, 2017, Journal of diabetes investigation.

Low serum testosterone levels are poor predictors of sexual dysfunction

M. Marberger, R. Rittmaster, T. Wilson, 2011, BJU international.

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

C. Roehrborn, M. Marberger, R. Rittmaster, 2006, The Journal of clinical endocrinology and metabolism.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)

T. Tammela, J. Nickel, R. Rittmaster, 2011, BJU international.

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

G. Cunningham, D. Hermann, R. V. Clark, 2004, The Journal of clinical endocrinology and metabolism.

Impact of multiple risk factors and ranitidine prophylaxis on the development of stress‐related upper gastrointestinal bleeding: A prospective, multicenter, double‐blind, randomized trial

C. Metz, J. S. Smith, D. Livingston, 1993 .

Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. The Ranitidine Head Injury Study Group.

C. Metz, J. S. Smith, D. Livingston, 1993, Critical care medicine.

A prospective randomised placebo‐controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

C. Roehrborn, M. Manyak, R. Rosen, 2018, BJU international.

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial

C. Roehrborn, G. Andriole, R. Rittmaster, 2011 .

Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlle

C. Roehrborn, M. Manyak, R. Rosen, 2020, International journal of clinical practice.

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH

C. Roehrborn, M. Manyak, O. Della Pasqua, 2019, World Journal of Urology.

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study

C. Roehrborn, M. Manyak, R. Rosen, 2018, International journal of clinical practice.

Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate‐to‐severe benign prostatic hyperplasia in Asian men

M. Manyak, Z. Ye, N. Masumori, 2018, International journal of urology : official journal of the Japanese Urological Association.

Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.

C. Roehrborn, L. Black, T. Wilson, 2012, The Journal of urology.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

C. Roehrborn, G. Andriole, J. Nickel, 2011, Urology.

The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4‐year data from the Combination of Avodart and Tamsulosin (CombAT) study

C. Roehrborn, F. Montorsi, M. Borre, 2011, BJU international.

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4‐year results from the randomized, double‐blind Combination of Avodart and Tamsulosin (CombAT) trial

C. Roehrborn, A. Tubaro, P. Siami, 2011, BJU international.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

C. Roehrborn, F. Montorsi, R. Castro, 2009, European urology.

Ranitidine is effective therapy for erosive esophagitis.

A. Euler, M. Silver, T. Wilson, 1993, The American journal of gastroenterology.

Acute appendicitis presenting as acute left scrotal pain: diagnostic considerations.

L. Holder, R. Raiker, T. Wilson, 1985, Urology.

PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.

R. Enns, F. Al-Kawas, Susan L. Johnson, 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effect of dutasteride on the risk of prostate cancer.

D. Tindall, D. Bostwick, T. Tammela, 2010, The New England journal of medicine.

Model‐based meta‐analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms

C. Roehrborn, M. Manyak, O. Della Pasqua, 2020, British journal of clinical pharmacology.

Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.

K. Murphy, B. Ahrén, M. C. Carr, 2017, Diabetes research and clinical practice.

Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia.

M. Kattan, C. Roehrborn, K. Slawin, 2006, Urology.

Gastrointestinal safety across the albiglutide development programme

Lawrence A Leiter, R. Reinhardt, T. Wilson, 2016, Diabetes, obesity & metabolism.

Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis

S. Piscitelli, M. Somerville, L. Parish, 2020 .

Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study

C. Roehrborn, M. Manyak, M. Oelke, 2014, World Journal of Urology.

Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies

C. Roehrborn, M. Manyak, M. Oelke, 2014, World Journal of Urology.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

N. Fleshner, D. Margel, R. Castro, 2013, The Journal of urology.

Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long‐term results from the combination of dutasteride and tamsulosin study

C. Roehrborn, F. Montorsi, Seung Hwan Lee, 2012, International journal of urology : official journal of the Japanese Urological Association.

Varicocele as the presenting sign of an abdominal mass.

T. Wilson, C. Roy, D. Horne, 1989, The Journal of urology.

Effect of dutasteride on the risk of prostate cancer.

D. Tindall, D. Bostwick, T. Tammela, 2010, The New England journal of medicine.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

N. Fleshner, D. Margel, R. Castro, 2013, Journal of Urology.

Evaluation of a weighted multiple comparison procedure

G. Koch, P. Westfall, M. Somerville, 2005 .